Virpax PharmaceuticalsVRPX
VRPX
About: Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
431% more capital invested
Capital invested by funds: $12.6K [Q2] → $66.8K (+$54.2K) [Q3]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
13% more funds holding
Funds holding: 8 [Q2] → 9 (+1) [Q3]
1.08% more ownership
Funds ownership: 0.89% [Q2] → 1.97% (+1.08%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for VRPX.
Financial journalist opinion
Neutral
Business Wire
4 weeks ago
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate.
Neutral
Business Wire
4 weeks ago
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the c.
Neutral
GlobeNewsWire
1 month ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants.
Neutral
Business Wire
1 month ago
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr.
Neutral
Business Wire
1 month ago
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per.
Negative
Benzinga
2 months ago
This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Neutral
Business Wire
4 months ago
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.
Neutral
Business Wire
4 months ago
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.
Neutral
Business Wire
4 months ago
Virpax Regains Compliance with Nasdaq Minimum Bid Price
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.
Positive
Benzinga
5 months ago
Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.
Charts implemented using Lightweight Charts™